Bringing Needed Structure to COVID-19 Drug Development

Bringing Needed Structure to COVID-19 Drug Development

Bringing Needed Structure to COVID-19 Drug DevelopmentPosted on April 2nd, 2020 by Dr. Francis CollinsCaption: Molecular map showing interaction between the spike protein (gold) of the novel coronavirus and the peptidase domain (blue) of human angiotensin-converting enzyme 2 (ACE2). The ACE2 protein resides on the surface of cells in many parts of the human body, including the heart and lungs. These ACE inhibitors lower blood pressure by causing blood vessels to relax. Since the COVID-19 outbreak, many people have wondered whether taking ACE inhibitors would be helpful or detrimental against coronavirus infection. References:[1] Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2.

About Us

At Wellness Axis we want to encourage habits of wellness, Increase awareness of factors and resources contributing to well-being, Inspire and empower individuals to take responsibility for their own health, and to support a sense of community. Wellness can be thought of as the quality or state of being in good health.

Subscribe to our newsletter!